Evolution from a first clinical demyelinating event to multiple sclerosis in the REFLEX trial: Regional susceptibility in the conversion to multiple sclerosis at disease onset and its amenability to subcutaneous interferon beta‐1a

BACKGROUND AND PURPOSE: In the REFLEX trial (ClinicalTrials.gov identifier: NCT00404352), patients with a first clinical demyelinating event (FCDE) displayed significantly delayed onset of multiple sclerosis (MS; McDonald criteria) when treated with subcutaneous interferon beta‐1a (sc IFN β‐1a) vers...

Descripción completa

Detalles Bibliográficos
Autores principales: Battaglini, Marco, Vrenken, Hugo, Tappa Brocci, Riccardo, Gentile, Giordano, Luchetti, Ludovico, Versteeg, Adriaan, Freedman, Mark S., Uitdehaag, Bernard M. J., Kappos, Ludwig, Comi, Giancarlo, Seitzinger, Andrea, Jack, Dominic, Sormani, Maria Pia, Barkhof, Frederik, De Stefano, Nicola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Multiple Sclerosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9321632/
https://www.ncbi.nlm.nih.gov/pubmed/35274413
http://dx.doi.org/10.1111/ene.15314

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9321632/
https://www.ncbi.nlm.nih.gov/pubmed/35274413
http://dx.doi.org/10.1111/ene.15314

Ejemplares similares